Zinc Finger Fusion Proteins Repress Alpha-Synuclein
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating Parkinson's disease, such as anti-sense oligonucleotides and monoclonal antibodies, are inadequate in effectively reducing alpha-synuclein levels and halting disease progression, as they require repeated dosing and have limited efficacy in targeting specific alpha-synuclein forms and intracellular activity.
Innovation Solution
Development of zinc finger protein (ZFP) domains fused with a transcription repressor domain to specifically inhibit the expression of the human SNCA gene, targeting sites near the transcription start sites to reduce alpha-synuclein production, which can be delivered via recombinant AAV vectors to brain cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-sense oligonucleotides or monoclonal antibodies are used to reduce alpha-synuclein levels, then some reduction in alpha-synuclein occurs, but the treatment requires repeated dosing and has limited efficacy
Solution Approach 1:
The patent uses recombinant AAV vectors to deliver zinc finger protein transcription factors that bind to the SNCA gene promoter region before alpha-synuclein overexpression can occur. This preliminary genetic intervention establishes sustained transcriptional repression, eliminating the need for repeated dosing and providing long-lasting therapeutic effect
Solution Approach 2:
The invention changes the therapeutic approach from targeting alpha-synuclein protein or mRNA (temporary effects) to targeting gene transcription at the DNA level. By using zinc finger proteins that bind to specific promoter sequences of the SNCA gene, the treatment fundamentally alters the expression parameter from transient reduction to sustained suppression
2Reliability
If current anti-synuclein therapies are administered, then some alpha-synuclein reduction is achieved, but off-target effects and limited specificity remain problematic
Solution Approach 1:
The zinc finger proteins are engineered with specific DNA-binding domains that recognize and bind to unique sequences in the SNCA gene promoter region. This localized specificity ensures that the transcriptional repression is targeted precisely to the alpha-synuclein gene without affecting other genes, eliminating off-target effects while maintaining high specificity
Solution Approach 2:
The patent introduces zinc finger protein transcription factors as intermediary molecules that mediate between the therapeutic goal (reducing alpha-synuclein) and the molecular target (SNCA gene promoter). These engineered proteins act as specific intermediaries that translate the therapeutic intent into precise gene-specific repression without broad-spectrum effects
3Duration of action of stationary object
If repeated dosing is used with current therapies, then some sustained effect is achieved, but treatment complexity and patient burden increase
Solution Approach 1:
The recombinant AAV vectors deliver self-sustaining genetic machinery (zinc finger protein transcription factors) that continuously produce the therapeutic effect without requiring external intervention. The viral vectors integrate or persist in the target cells, enabling the cells to self-regulate alpha-synuclein expression long-term, thereby simplifying treatment administration to a single dose
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ZFP domain approach effectively represses alpha-synuclein expression by up to 99% with minimal off-target activity, potentially slowing or halting Parkinson's disease progression with a single administration, offering a more robust and sustained therapeutic effect compared to existing treatments.
Implementation Method 1
These fusion proteins contain (i) a ZFP domain that binds specifically to a target region in the SNCA gene
Implementation Method 2
a transcription repressor domain that reduces the transcription of the gene
Implementation Method 3
which can be delivered via recombinant AAV vectors to brain cells
Data Source
AI summary
The present disclosure provides zinc finger fusion proteins that inhibit expression of alpha-synuclein in the nervous system, and methods of using the proteins to treat Parkinsons disease, Lewy body dementia, multiple system atrophy, Alzheimers disease, and other neurodegenerative diseases.